. 2011 Sep;85(17):9039–9050. doi: 10.1128/JVI.02675-10

Table 3.

Synergy between GRFT and b12 for neutralization of HIV-1

HIV-1 envelope pseudovirus	Single				Combined				CI^a
	GRFT		b12		GRFT		b12		CI^a
	IC₅₀^b (μg/ml)	IC₈₀^c (μg/ml)	IC₅₀ (μg/ml)	IC₈₀ (μg/ml)	IC₅₀ (μg/ml)	IC₈₀ (μg/ml)	IC₅₀ (μg/ml)	IC₈₀ (μg/ml)	IC₅₀ (μg/ml)	IC₈₀ (μg/ml)
QH0692.42	0.002	0.008	1.2	2.8	0.001	0.005	0.09	0.05	0.6	0.6
QH0692-N386Q	0.004	0.03	0.6	2.0	0.004	0.02	0.003	0.2	1.0	0.8
COT6.15	0.06	0.2	33.6	ND^d	0.03	0.1	5.6	18.6	0.7	ND
COT6-V295N/S448N	0.003	0.008	44.1	ND	0.002	0.006	0.02	0.9	0.7	ND
COT6-V295N/S448N/N386Q	0.001	0.004	1.1	3.8	0.002	0.3	0.02	11.0	2.0	1.0
Du151.2	0.03	0.1	0.3	0.7	0.03	0.1	0.3	0.9	1.3	2.2
COT9.6	0.1	0.4	1.7	9.0	0.06	0.3	2.2	11.0	1.9	2.0

A CI of 0.3 to 0.7 indicates synergism, 0.7 to 0.85 indicates moderate synergism, 0.85 to 0.9 indicates slight synergism, and 0.9 to 1.1 indicates an additive effect. Cases where synergism occurred are in boldface.

The IC₅₀ is the concentration needed to reduce HIV-1 infection by 50%.

The IC₈₀ is the concentration needed to reduce HIV-1 infection by 80%.

ND, not determined.